The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $100,000 to Edunn Biotechnology, Inc., an early stage company dedicated to developing a novel class of drugs to treat and prevent Alzheimer's disease (AD). Edunn's lead drug candidate, EDN-OL1, is an oligonucleotide-based drug that has shown promise in halting and reversing the progression of AD in animal models.